Sentiment for Newlink Genetics Corp (NASDAQ:NLNK)
Newlink Genetics Corp (NASDAQ:NLNK) institutional sentiment decreased to 0.57 in 2019 Q2. Its down -0.25, from 0.82 in 2019Q1. The ratio dropped, as 21 institutional investors increased or started new positions, while 37 sold and reduced stakes in Newlink Genetics Corp. The institutional investors in our partner’s database now possess: 10.32 million shares, down from 12.32 million shares in 2019Q1. Also, the number of institutional investors holding Newlink Genetics Corp in their top 10 positions was flat from 0 to 0 for the same number . Sold All: 17 Reduced: 20 Increased: 11 New Position: 10.
NewLink Genetics Corporation, a biopharmaceutical company, focuses on discovering, developing, and commercializing immunotherapeutic products for the treatment of cancer. The company has market cap of $58.96 million. The Company’s portfolio includes biologic product candidates based on its HyperAcute cellular immunotherapy technology, which is designed to stimulate the human immune system to attack cancer cells; and small-molecule product candidates that are focused on breaking the immune system's tolerance to cancer by inhibiting the indoleamine-2, 3-dioxygenase pathway and the tryptophan-2, 3-dioxygenase pathway. It currently has negative earnings. The firm is developing IDO pathway inhibitors comprising indoximod that is in multiple Phase I and Phase II clinical trials for patients with melanoma, pancreatic cancer, malignant brain tumors, metastatic breast cancer, acute myeloid leukemia, prostate cancer, and non-small cell lung cancer ; and GDC-0919 and atezolizumab (MPDL3280A) that is in Phase Ib clinical trials for patients with locally advanced or metastatic solid tumors.
The stock increased 2.60% or $0.04 during the last trading session, reaching $1.58. About 262,706 shares traded. NewLink Genetics Corporation (NASDAQ:NLNK) has declined 52.80% since December 4, 2018 and is downtrending. It has underperformed by 52.80% the S&P500.
Analysts await NewLink Genetics Corporation (NASDAQ:NLNK) to report earnings on February, 26. They expect $-0.28 earnings per share, 0.00 % or $0.00 from last year’s $-0.28 per share. After $-0.27 actual earnings per share reported by NewLink Genetics Corporation for the previous quarter, Wall Street now forecasts 3.70 % negative EPS growth.
Connor Clark & Lunn Investment Management Ltd. holds 0.01% of its portfolio in NewLink Genetics Corporation for 583,084 shares. Acadian Asset Management Llc owns 546,290 shares or 0% of their US portfolio. Moreover, Aperio Group Llc has 0% invested in the company for 88 shares. The North Carolina-based Bank Of America Corp De has invested 0% in the stock. Bank Of Montreal Can, a Ontario – Canada-based fund reported 1,967 shares.
More notable recent NewLink Genetics Corporation (NASDAQ:NLNK) news were published by: Seekingalpha.com which released: “NewLink Genetics: Explicating The Changing Fundamentals Of A Potential Comeback – Seeking Alpha” on May 17, 2018, also Benzinga.com with their article: “Stocks That Hit 52-Week Lows On Wednesday – Benzinga” published on October 02, 2019, Seekingalpha.com published: “NewLink -1.3% on Lumos merger – Seeking Alpha” on September 30, 2019. More interesting news about NewLink Genetics Corporation (NASDAQ:NLNK) were released by: Seekingalpha.com and their article: “FDA accepts NewLink’s partnered BLA for ebola vaccine – Seeking Alpha” published on September 17, 2019 as well as Globenewswire.com‘s news article titled: “NewLink Genetics Reports First Quarter 2019 Financial Results and Provides Clinical Activities Update – GlobeNewswire” with publication date: May 08, 2019.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.